{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:08:06Z","timestamp":1788566886863,"version":"build-2803163510"},"reference-count":34,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.2217\/imt-2020-0105","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T12:12:20Z","timestamp":1594642340000},"page":"785-798","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":38,"title":["Serum Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Prognosticating Immunotherapy Efficacy"],"prefix":"10.1080","volume":"12","author":[{"given":"Adi","family":"Kartolo","sequence":"first","affiliation":[{"name":"Cancer Care of Southeastern Ontario, Department of Medical Oncology, Kingston, OntarioK7L 2V7, Canada"},{"name":"Queen's University, Kingston, Ontario\ufffd\ufffdK7L 2V7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Holstead","sequence":"additional","affiliation":[{"name":"Cancer Care of Southeastern Ontario, Department of Medical Oncology, Kingston, OntarioK7L 2V7, Canada"},{"name":"Queen's University, Kingston, Ontario\ufffd\ufffdK7L 2V7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Khalid","sequence":"additional","affiliation":[{"name":"Cancer Care of Southeastern Ontario, Department of Medical Oncology, Kingston, OntarioK7L 2V7, Canada"},{"name":"Queen's University, Kingston, Ontario\ufffd\ufffdK7L 2V7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Emack","sequence":"additional","affiliation":[{"name":"Cancer Care of Southeastern Ontario, Department of Medical Oncology, Kingston, OntarioK7L 2V7, Canada"},{"name":"Queen's University, Kingston, Ontario\ufffd\ufffdK7L 2V7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Hopman","sequence":"additional","affiliation":[{"name":"Queen's University, Kingston, Ontario\ufffd\ufffdK7L 2V7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Robinson","sequence":"additional","affiliation":[{"name":"Cancer Care of Southeastern Ontario, Department of Medical Oncology, Kingston, OntarioK7L 2V7, Canada"},{"name":"Queen's University, Kingston, Ontario\ufffd\ufffdK7L 2V7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Baetz","sequence":"additional","affiliation":[{"name":"Cancer Care of Southeastern Ontario, Department of Medical Oncology, Kingston, OntarioK7L 2V7, Canada"},{"name":"Queen's University, Kingston, Ontario\ufffd\ufffdK7L 2V7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3708"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.1184"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_160766"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S153290"},{"issue":"74","key":"e_1_3_3_7_1","first-page":"1","article-title":"Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab","volume":"6","author":"Capone M","year":"2018","unstructured":"Capone M , GiannarelliD , MallardoDet al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J. Immunother. Cancer6(74), 1\u20137 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2596"},{"issue":"1","key":"e_1_3_3_9_1","first-page":"mdzo27.004","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors","volume":"30","author":"Amaral SR","year":"2019","unstructured":"Amaral SR , MouraMC , CarvalhoJet al. Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors. Ann. Oncol.30(supplement1), mdzo27.004 (2019).","journal-title":"Ann. Oncol."},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12815"},{"issue":"4","key":"e_1_3_3_11_1","first-page":"351","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"3","author":"Mezauita L","year":"2019","unstructured":"Mezauita L , AuclinE , FerraraR. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol.3(4), 351\u2013357 (2019).","journal-title":"JAMA Oncol."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31778"},{"issue":"5","key":"e_1_3_3_13_1","first-page":"1016","article-title":"Revisiting the hallmarks of cancer","volume":"7","author":"Fouad Y","year":"2017","unstructured":"Fouad Y , AaneiC. Revisiting the hallmarks of cancer. Am. J. Cancer Res.7(5), 1016\u20131036 (2017).","journal-title":"Am. J. Cancer Res."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2016.09.007"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.139.7.2406"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.134.1.230"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161211795049804"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199603000-00011"},{"issue":"1","key":"e_1_3_3_20_1","first-page":"1","article-title":"Platelet function in anaphylaxis","volume":"16","author":"Kasperska-Zajc A","year":"2006","unstructured":"Kasperska-Zajc A , RogalaB. Platelet function in anaphylaxis. J. Investig. Allergol Clin. Immunol.16(1), 1\u20134 (2006).","journal-title":"J. Investig. Allergol Clin. Immunol."},{"key":"e_1_3_3_21_1","first-page":"18","article-title":"Platelet contribution to cancer cell growth and migration: the role of platelet growth factors","volume":"18","author":"Poggi A","year":"1988","unstructured":"Poggi A , VicenziE , CioceVet al. Platelet contribution to cancer cell growth and migration: the role of platelet growth factors. Haemostasis18, 18\u201328 (1988).","journal-title":"Haemostasis"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910600324"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07205"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2011.08.001"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-016-1452-x"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0789-x"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006029"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.09.028"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1455706"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.COC.0000017093.79897.DE"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1089\/10799900260286623"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2123"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14155"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.006"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000457"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2020-0105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:24:07Z","timestamp":1715984647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2020-0105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.2217\/imt-2020-0105"],"URL":"https:\/\/doi.org\/10.2217\/imt-2020-0105","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}